Exro Announces US$30 Million Credit Facility, Plan to Seek Debentureholder Consent, and Strategic Review Process
CALGARY, AB, May 16, 2025 /PRNewswire/ - Exro Technologies Inc. (TSX: EXRO) ("Exro" or the "Company"), a leading clean technology company specializing in power control solutions for electric vehicles and energy storage, is pleased to announce a funding commitment from a long-term institutional shareholder (the "Lender") to provide up to US$30 million pursuant to a senior secured loan facility (the "Facility").
The proceeds of the Facility will enable Exro to maintain operations and execute its business plan while advancing a strategic review process supported by an independent strategic advisor (the "Strategic Advisor") who has been retained by the Company. The review is intended to evaluate a range of outcomes including strategic partnerships, capital restructuring, M&A opportunities, and other corporate transactions.
The Facility
The Facility is a secured, non-revolving, multiple-draw credit facility. Highlights include:
Facility Size: Up to US$30 million
Disbursements: Funds will be advanced in milestone-based tranches, with the initial tranche of US$2 million expected to be advanced on May 20, 2025. Milestones are set out below.
Convertible Debenture Condition: A condition of the second milestone-based tranche is that the Company shall have either (1) obtained a postponement of security from a requisite majority of debentures issued pursuant to an indenture dated December 30, 2022 (the "Convertible Debentures"), or (2) issued a redemption notice pursuant to which the Convertible Debentures would be redeemed in exchange for shares.
Use of Proceeds: Working capital, implementation of the strategic plan, and retention of advisors and legal support.
Non-Convertible: The facility is not convertible into equity.
Warrants: Subject to receipt of TSX approval, the Lender will be issued warrants to purchase up to 75 million common shares at a nominal price.
Milestones
The milestones for advances under the Facility are as follows;
Milestones 1 – funds to be advanced no earlier than June 6, 2024
May 20, 2025
Establish initial operating plan for the Company acceptable to the Lender
Establish initial 13 week Cash Flow acceptable to the Lender
May 30, 2025
Engagement Letter(s) executed by Exro with such external advisors recommended by the Strategic Advisor and acceptable to the Lender
June 3, 2025
Holders of the Convertible Debentures consent to the postponement of security in favour of the Interim Lender or notices of redemption issued in respect of the Convertible Debentures
Milestones 2 – funds to be advanced no earlier than July 15, 2025
June 15, 2025
Execution of operating plan by Exro acceptable to the Lender
July 1, 2025
If not otherwise postponed to the Interim Lender per the terms of the Facility, conclusion of the redemption of the Convertible Debentures and issuance of common shares in the capital of Exro in payment thereof.
July 15, 2025
Evidence of active engagement with at least three (3) credible strategic partners in accordance with operating plan, as assessed by the Strategic Advisor
Milestone 3 – funds to be advanced no earlier than September 30, 2025
July 15, 2025
Execution of operating plan by Exro in a manner acceptable to the Lender
Sept 1, 2025
Execution of definitive contract(s) with credible strategic partners in accordance with operating plan, as assessed by the Strategic Advisor
Debentureholder Consent
Exro has C$15 million of senior secured Convertible Debentures outstanding, with a first lien over substantially all of the Company's assets. Exro also has senior secured notes (the "Notes") outstanding, secured by substantially all of the Company's assets but subordinate to the Convertible Debentures.
The Company intends to solicit a postponement of security from a requisite majority of the Convertible Debentures. The postponement of security, if obtained, would result in:
the Facility and the Notes being secured by a first lien; and
the Convertible Debentures being secured by a second lien.
In the alternative, the Company has the contractual right (subject to TSX approval) to redeem the Convertible Debentures for shares. Pursuant to the Indenture, the redemption price is equal to 105% of par value plus 100% of accrued interest, with consideration being common shares issued at a share price based on the 5-day volume weighted average price of the shares for the five business days preceeding issuance of the redemption notice.
Strategic Wind-Down of APAC Subsidiary
As part of its focus on core markets and capital efficiency, Exro has initiated an orderly wind-down of its Australia-based subsidiary. Legal counsel has been retained, and the Company is working to resolve all lease, employment, and regulatory matters. This strategic decision supports the Company's ongoing focus on cost reductions and reallocation of resources to high-impact markets with stronger commercial traction and more efficient capital deployment.
Looking Ahead
Exro is entering a pivotal phase with the financial flexibility and strategic lens to evaluate a range of opportunities that align with its core technology and market focus. The ongoing strategic process is designed to unlock value—whether through partnerships, transactions, or focused execution on high-impact initiatives. With strengthened capital backing and a clear mandate, Exro remains committed to pursuing the best path forward for its shareholders.
ABOUT EXRO TECHNOLOGIES INC.
Exro Technologies Inc., now expanded through the strategic acquisition of SEA Electric, is a leading clean technology company that has developed new-generation power control electronics. Its innovative suite of solutions, including Coil Driver™, Cell Driver™, and SEA-Drive®, expand the capabilities of electric motors and batteries and offer OEMs a comprehensive e-propulsion solution with unmatched performance and efficiency. Exro is reshaping global energy consumption, accelerating adoption towards a circular electrified economy by delivering more with less – minimum energy for maximum results.
For more information visit our website at www.exro.com.
To view our Corporate Presentation visit us at www.exro.com/investors
Visit us on social media @exrotech.
CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS
This news release contains forward-looking statements and forward-looking information (together, "forward-looking statements") within the meaning of applicable securities laws. All statements, other than statements of historical facts, are forward-looking statements. Generally, forward-looking statements can be identified using terminology such as "plans", "expects", "estimates", "intends", "anticipates", "believes" or variations of such words, or statements that certain actions, events or results "may", "could", "would", "might", "will be taken", "occur" or "be achieved". Forward looking statements involve risks, uncertainties and other factors disclosed under the heading "Risk Factors" and elsewhere in the Company's filings with Canadian securities regulators, that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Although the Company believes that the assumptions and factors used in preparing these forward-looking statements are reasonable based upon the information currently available to management as of the date hereof, actual results and developments may differ materially from those contemplated by these statements. Readers are therefore cautioned not to place undue reliance on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed times frames or at all. Except where required by applicable law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
This information is qualified in its entirety by cautionary statements and risk factor disclosure contained in filings made by the Company with the Canadian securities regulators, including the Company's annual information form for the financial year ended December 31, 2024, and financial statements and related MD&A for the financial year ended December 31, 2024, filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedarplus.ca. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties, and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated, or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
Neither the Toronto Stock Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/exro-announces-us30-million-credit-facility-plan-to-seek-debentureholder-consent-and-strategic-review-process-302457464.html
SOURCE Exro Technologies Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Beef prices surge as barbecue season approaches
Canadians looking to grill some burgers and steaks as the summer barbecue season heats up may find themselves paying much more for beef, prompting one food expert to call for an investigation. Prices for striploin steak are 34.2 per cent higher since January, while top sirloin is up 33.7 per cent, according to Statistics Canada. Pork ribs and chicken breasts are each up 5.9 per cent during the same period. 'For many Canadian families, a summer steak on the grill is starting to feel more like a splurge than a staple,' Sylvain Charlebois, director of the Agri-Food Analytics Lab at Dalhousie University, said in a recent report. 'Consumers will continue to enjoy beef, but with moderation and on occasions that justify the cost.' He pointed to several factors behind the jump in beef prices, including transportation costs, the carbon tax, the number of licensed beef processors and labour costs. Canadian inventory is also an issue since it has fallen to 3.38 million head, the lowest level since 1989. 'Many cattle producers are exiting the industry while prices are favourable, opting to reinvest in less volatile sectors or shift entirely to crop production,' Charlebois said. 'In short, the Canadian beef industry is retreating and becoming increasingly risk-averse.' Canadians are already taking notice of the price hikes in the past few years. Per capita beef consumption fell 7.1 per cent in 2023 and another 2.1 per cent in 2024, according to IBISWorld data. 'This is no longer just a matter of shifting dietary preferences; it's a structural shift in consumer behaviour,' Charlebois said. 'Beef is increasingly seen as a luxury item, with ground beef becoming the primary choice for budget-conscious households still committed to red meat.' He also wonders if producers in Canada are taking advantage of the situation. In the United States, former president Joe Biden tried to crack down on anticompetitive practices in the food industry, specifically price fixing in the meat sector. In February, Brazilian meatpacking company JBS SA agreed to pay US$83.5 to settle claims that it worked with other companies to artificially inflate prices. Under the settlement, JBS must also work with U.S. investigators looking into similar claims at Tyson Foods Inc., Cargill Inc. and National Beef Packing Co. LLC. JBS has called the claims against it 'frivolous and without merit,' but is settling because it is in the company's best interest. 'The Canadian Competition Bureau, by contrast, has remained largely silent on similar concerns,' Charlebois said. 'Perhaps it's time for that to change.' Prices on thousands of grocery items to rise despite tariff break, says Loblaw Canada has lost its global agricultural trading edge, RBC report says The Competition Bureau said investigations are confidential, so it can not reveal information on current investigations. 'The bureau must conduct a thorough and complete examination of the facts regarding any issue before reaching any conclusion as to whether the Competition Act has been contravened,' a spokesperson for the agency said in a statement. 'If we find evidence of activities that could raise concerns under the law, we will take action.' • Email: bcousins@ Sign in to access your portfolio
Business Insider
3 hours ago
- Business Insider
I landed a remote job for a European company, and now I'd find it hard to go back to a US-based company — I feel spoiled by the perks
This as-told-to essay is based on a transcribed conversation with 34-year-old Meghan Gezo, from Michigan. The following has been edited for length and clarity. In 2022, I left my job working remotely in people operations for a US company. Juggling my job and raising my one-year-old wasn't working. I wanted to take a break while I looked for another opportunity that would allow me to have better work-life boundaries. After a few months of job hunting, I started as a people experience manager at Storyblok, a fully remote content management company based in Austria. I'd never worked for a company based in Europe before. Living in the US, most jobs that pop up are US-based. People have come to expect more work-life balance in Europe, as the employment laws differ from the US. For me, there have been perks related to my life as a parent, my working hours, and my professional growth. I was immediately drawn to the benefits of working for a European company I've been working in remote jobs for tech companies since 2016. I'd previously worked in an office, but thought a remote job meant I could focus on higher-impact work than the office administration that usually fell to HR, as well as branch out beyond the manufacturing and automotive industry jobs in my area. It was easier to find a remote job in 2022 than in 2016. I found the listing for Storyblok on a job board. The people I spoke with were genuine and direct. In the first interview, they talked about time off norms and said the standard workweek is 38.5 hours. They seemed to emphasize work-life balance and gave me concrete examples of how it worked at the company. I was optimistic I could be successful in the role while staying involved in my daughter's life. In the US, the norm on paper is a 40-hour workweek, but in practice, people often work until they finish their tasks, especially in tech. I used to work, feed my daughter, put her to bed, and then work some more. It felt normal. At my current company, you focus on work when you're at work and then log off until the next day. There have definitely been times when I've had to work extra hours, but overall, I'd say that my work-life balance is better. In the US, it can often feel that your work is your identity. My European colleagues take pride in their work and are extremely hard workers, but their job is one facet of their identity. Working for a European company has pushed me in new ways I've gained experience working with people from other cultures. Learning about Austrian law has also pushed me to expand my HR knowledge beyond US employment law. One thing I've noticed about the company culture is that when people are on vacation, they're on vacation. Meanwhile, it's more the norm in the US to answer messages on vacation. I've not completely broken this habit, but it has felt more attainable for me to delete work communication apps from my phone when I'm away. I've felt very supported in my role as a parent at my European company The Austrian norm of " care leave," which isn't a norm in the US, is a great part of working for a European company. Because I have kids under a certain age, I get to use two paid weeks off a year for days when my kids are sick and I need to take them to a doctor or take care of them. Having this bucket to pull from is a huge weight off my shoulders as a parent. My previous employers had generous parental leave policies. However, at Storyblok, I got slightly more time — 16 weeks. I went on maternity leave at a previous company with my firstborn and again at my current job in 2023. During my most recent maternity leave, people in the company treated it very seriously. I got a lot of support from my manager and team to help plan for my leave and assign my tasks to others. During my first maternity leave for a previous company, I didn't mind answering a few questions as needed to support my team, but at Storyblok, no one asked me work-related questions while I was away. There are some downsides While my working hours suit my season of life, there are days when I wish I could start later at 9 a.m. However, I don't think I'd be as effective without overlap with my European colleagues. Right now, I work 6:30 a.m. to 2:30 p.m. ET. Sometimes, if I have a question I want to ask colleagues in Europe during my afternoons, I'll know that I won't be getting an answer until the next day because of the time zone difference. I've learned to work these expectations into my regular workflow. It does make me sad that I don't live near my colleagues. I've built strong relationships with these people, but they're an ocean away. I'd find it hard to go back to a US-based company Working for a European company didn't occur to me as an option before I interviewed for this job. Having worked here for over two years, I feel spoiled by the benefits and perks of European working culture, and it would be hard for me to go back to working for a US-based company.
Yahoo
8 hours ago
- Yahoo
Nucleus Genomics Launches Nucleus Embryo, Genetic Optimization Software Alongside Partnership with Genomic Prediction
Parents pursuing IVF now have a new level of choice to empower their family planning NEW YORK, June 4, 2025 /PRNewswire/ -- With U.S. birthrates plummeting and IVF on the rise, Nucleus Genomics today launched Nucleus Embryo, the first genetic optimization software that lets parents see and understand a complete genetic profile to select an embryo. "Before there's a heartbeat, there's DNA," said Kian Sadeghi, founder and CEO of Nucleus. "One file containing DNA and genetic markers can tell you more about your baby's future than any other test a doctor could possibly run at this stage. Most clinics stop at whether an embryo will develop. For many parents, that's not enough. Patients have long asked for more transparency from clinics, and Nucleus Embryo is an important step toward complete data ownership for parents planning their families." The software enables parents to analyze and compare up to 20 embryos across over 900 hereditary conditions and 40 additional analyses beyond basic viability, spanning cancers, chronic conditions, appearance, cognitive ability, mental health, and more. To widen access to the software, Nucleus will partner with Genomic Prediction, the first company to offer genome-wide screening on embryos. The partnership sets a new standard in genetic medicine, continuing Genomic Prediction's decade-long history of giving hopeful parents the best possible chance of implanting healthy embryos. The company's analyses focus on hereditary conditions, acting as the first line of defense against chronic and rare diseases. "As an organization, we are committed to supporting patients' rights to their DNA and any information that can aid in their family-building journey," said Kelly Ketterson, CEO of Genomic Prediction. "We have a legacy of innovation aimed at providing patients with access to the best scientific resources. Our partnership with Nucleus opens access to information our patients have requested and allows us to uphold our commitment to this legacy." Nucleus' partnership with Genomic Prediction reflects a growing shift in how parents think about genetics as a tool to give children the best possible start in life. A wide-ranging study of Americans found the majority accepted the use of genetic technology to choose embryos based on health and personality traits. Four in 10 parents would use genetic optimization as another tool to understand their future child's cognitive abilities. Most women undergo three to six IVF cycles before successfully having a baby, with each cycle costing up to $25,000. Many embryos are unviable within days of being fertilized, leaving parents with few to choose from. Facing high stakes, clinicians often recommend genetic testing to optimize a couple's chances of a healthy pregnancy. But these tests typically stop at a select number of hereditary conditions and chromosome count. Now, advanced genetic analysis from Nucleus gives parents a new window into the health and well-being of their future child. Nucleus Embryo provides a comprehensive genetic profile for each embryo, encompassing hereditary genetic diseases, like cystic fibrosis and hemochromatosis, alongside genetic measures of cognitive ability, mental health, and risk for chronic diseases. Wide access to genetic insights for embryos can also help extend lifespan from the earliest stages of life. While more than half of all deaths annually in the U.S. are attributed to chronic, age-related conditions — such as Alzheimer's disease, diabetes, cancer, and heart disease — research shows embryonic selection can materially help reduce disease risk for these conditions. "We celebrate health optimization and the pursuit of longevity in every other part of life via our focus on training, supplements, and sleep," Sadeghi said. "We all know health isn't just the absence of disease. It's the ability to understand our bodies and genetic makeup to reach our full potential. Now we can apply this principle to life's inception." About Nucleus Genomics Nucleus builds software for generational health. Inspired by the loss of his cousin who died of a rare — yet preventable — genetic disease, Nucleus founder and Thiel Fellow Kian Sadeghi left an Ivy League university to build a product that could have saved her life. Our advanced DNA health test and analysis takes the guesswork out of your health, whether it's perfecting your protocols, knowing your risk for cancer, or planning for a healthy family. Follow us on social media @nucleusgenomics. About Genomic Prediction Genomic Prediction, Inc. is the frontrunner in advanced embryo screening. Our proprietary LifeView platform is state-of-the-art technology that assesses embryos for genetic health aimed at improved IVF outcomes. The LifeView Embryo Health Score Test (EHS) offers insight into the likelihood of developing conditions driven by multiple genes. It tests for significant health issues, including cardiovascular disease, diabetes mellitus, certain cancers, and mental health conditions. The EHS results are derived from the same embryo sample used in the following PGT tests: PGT-A: Identifies chromosome abnormalities in embryos. PGT-A+: Pinpoints the origin (paternal, maternal, or embryonic) of chromosome abnormalities. PGT-M: Decreases the chances of passing on monogenic (single-gene) conditions. PGT-SR: Detects chromosome abnormalities and structural imbalances, providing clarity between normal and balanced chromosomes. View original content to download multimedia: SOURCE Nucleus
